152 related articles for article (PubMed ID: 19082994)
1. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Jetter A; Kinzig M; Rodamer M; Tomalik-Scharte D; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2009 Apr; 65(4):411-7. PubMed ID: 19082994
[TBL] [Abstract][Full Text] [Related]
2. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
Jetter A; Kinzig-Schippers M; Illauer M; Hermann R; Erb K; Borlak J; Wolf H; Smith G; Cascorbi I; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
[TBL] [Abstract][Full Text] [Related]
3. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
4. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
6. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
Nyéki A; Buclin T; Biollaz J; Decosterd LA
Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
[TBL] [Abstract][Full Text] [Related]
7. Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans.
Djordjevic N; Carrillo JA; Roh HK; Karlsson S; Ueda N; Bertilsson L; Aklillu E
J Clin Pharmacol; 2012 Oct; 52(10):1527-34. PubMed ID: 22105431
[TBL] [Abstract][Full Text] [Related]
8. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
10. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
11. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
Relling MV; Lin JS; Ayers GD; Evans WE
Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
[TBL] [Abstract][Full Text] [Related]
12. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
Tsutsumi K; Kotegawa T; Matsuki S; Tanaka Y; Ishii Y; Kodama Y; Kuranari M; Miyakawa I; Nakano S
Clin Pharmacol Ther; 2001 Aug; 70(2):121-5. PubMed ID: 11503005
[TBL] [Abstract][Full Text] [Related]
13. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping.
Tang BK; Kadar D; Qian L; Iriah J; Yip J; Kalow W
Clin Pharmacol Ther; 1991 Jun; 49(6):648-57. PubMed ID: 2060254
[TBL] [Abstract][Full Text] [Related]
14. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay.
Rihs HP; John A; Scherenberg M; Seidel A; Brüning T
Clin Chim Acta; 2007 Feb; 376(1-2):240-3. PubMed ID: 17011540
[TBL] [Abstract][Full Text] [Related]
15. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
Krul C; Hageman G
J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
[TBL] [Abstract][Full Text] [Related]
16. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
Vrtic F; Haefeli WE; Drewe J; Krähenbühl S; Wenk M
Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
[TBL] [Abstract][Full Text] [Related]
17. Genistein alters caffeine exposure in healthy female volunteers.
Chen Y; Xiao CQ; He YJ; Chen BL; Wang G; Zhou G; Zhang W; Tan ZR; Cao S; Wang LP; Zhou HH
Eur J Clin Pharmacol; 2011 Apr; 67(4):347-353. PubMed ID: 21222115
[TBL] [Abstract][Full Text] [Related]
18. [The acetylator polymorphism in a Khmer population: clinical consequences].
Bechtel YC; Bechtel PR; Lelouët H; Choisy H; Dy NR
Therapie; 2001; 56(4):409-13. PubMed ID: 11677864
[TBL] [Abstract][Full Text] [Related]
19. Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping.
Wong P; Banerjee K; Massengill J; Nowell S; Lang N; Leyland-Jones B
J Immunol Methods; 2001 May; 251(1-2):1-9. PubMed ID: 11292476
[TBL] [Abstract][Full Text] [Related]
20. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
